Urinary phthalate metabolites over the first 15months of life and risk assessment - CHECK cohort study

Sunmi Kim1, Jangwoo Lee1, Jeongim Park2

  • 1School of Public Health, Seoul National University, Seoul 08826, Republic of Korea.

Insights

Infant phthalate exposure, particularly to di(2-ethylhexyl) phthalate (DEHP), increases with age in Korea. Consistent exposure sources are identified, with significant health risks emerging by 15 months.

Area of Science:

  • Environmental Health
  • Pediatric Toxicology
  • Endocrine Disruptors

Background:

  • Phthalates are endocrine disruptors with infants and young children being particularly vulnerable.
  • Limited data exists on phthalate exposure during early life stages.
  • Understanding temporal trends and risks is crucial for this sensitive population.

Purpose of the Study:

  • To investigate the temporal trends of major phthalate exposure in Korean infants up to 15 months postpartum.
  • To estimate the health risks associated with phthalate exposure in this age group.
  • To identify persistent exposure sources during early development.

Main Methods:

  • Analysis of four major phthalates (DEHP, DiBP, DnBP, DEP) via their urinary metabolites.
  • Collection of 286 urine samples from 171 infants at 3, 9, 12, and 15 months of age.
  • Calculation of Hazard Quotients (HQ) and Hazard Indices (HI) to assess risk.

Main Results:

  • Di(2-ethylhexyl) phthalate (DEHP) metabolites detected in 100% of samples at high levels, exceeding international comparisons.
  • Urinary phthalate metabolite concentrations, especially DEHP, increased with infant age.
  • Significant percentages of children exceeded risk thresholds (HI>1) by 12 (16%) and 15 (26%) months, primarily due to DEHP.

Conclusions:

  • Consistent and increasing phthalate exposure, particularly DEHP, occurs in Korean infants.
  • This exposure poses significant health risks, warranting urgent investigation into sources and mitigation strategies.
  • Early life phthalate exposure requires focused public health attention due to endocrine disruption concerns.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
63
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K